๐ฌDeep Research
ANVS โ Annovis Bio Inc ยท catalysts, narrative & risks
Company Snapshot
Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company headquartered in Malvern/Berwyn, Pennsylvania, developing the investigational once-daily oral therapy buntanetap (announced as formerly "posiphen" [1], [2]) for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). It is not part of a major headline index [5]. Below is a point-in-time review as of 2026-10-04; it is descriptive, not investment advice.
Recent Catalysts (last ~1โ3 months)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ